DPx Holdings B.V. Donates to Hospitals and Organizations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

DPx Holdings B.V. Donates to Hospitals and Organizations


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

DPx Holdings B.V., a provider of custom manufacturing, technologies, and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries, donated $110,000 to more than 20 different hospitals and organizations across the globe.

DPx Holdings B.V. was formed earlier this year as a result of a merger between Patheon and DSM Pharmaceutical Products. The company is comprised of three core business units, Patheon Pharma Services, DSM Fine Chemicals, and Banner Life Sciences.

The $5,000 donations were made on behalf of each site to thank employees for their efforts to help improve the lives of patients. Each site selected a local hospital or organization that makes a direct impact on patients in the community.

Source: DPx Holdings B.V.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here